STX209 (Arbaclofen) for autism spectrum disorders: An 8-week open-label study

Journal of Autism and Developmental Disorders

Volumn 44, Issue 4, 2014, Pages 958-964

  Erickson, Craig A ^a   Veenstra Vanderweele, Jeremy M ^b   Melmed, Raun D ^c   McCracken, James T ^d   Ginsberg, Lawrence D ^e   Sikich, Linmarie ^f   Scahill, Lawrence ^g   Cherubini, Maryann ^h   Zarevics, Peter ^h   Walton Bowen, Karen ^h   Carpenter, Randall L ^h   Bear, Mark F ⁱ   Wang, Paul P ^h   King, Bryan H ^j  

^a CINCINNATI CHILDREN'S HOSPITAL MEDICAL CENTER   (United States)

^b VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

^c Ctr for Executive Res   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

^e Red Oak Psychiatry Associates   (United States)

^f UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^g EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^h Seaside Therapeutics Inc   (United States)

ⁱ MASSACHUSETTS INSTITUTE OF TECHNOLOGY   (United States)

^j UNIVERSITY OF WASHINGTON   (United States)

more..

Author keywords

Arbaclofen; Autism spectrum disorder; Clinical trial; Gamma aminobutyric acid (GABA); STX209

Indexed keywords

ARBACLOFEN; BACLOFEN;

ABERRANT BEHAVIOR CHECKLIST IRRITABILITY SUBSCALE; ADOLESCENT; AGGRESSION; AGITATION; ARTICLE; ATTENTION DISTURBANCE; AUTOMUTILATION; BEHAVIOR DISORDER; CHILD; CLINICAL ARTICLE; CLINICAL GLOBAL IMPRESSION SCALE; CLINICAL TRIAL; COUGHING; DECREASED APPETITE; DIARRHEA; DIZZINESS; DRUG DOSE INCREASE; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG SAFETY; DRUG SUBSTITUTION; DRUG TOLERABILITY; DRUG WITHDRAWAL; FATIGUE; FEMALE; FOLLOW UP; HEADACHE; HUMAN; HYPERACTIVITY; IMPULSIVENESS; INSOMNIA; IRRITABILITY; LETHARGY SOCIAL WITHDRAWAL SUBSCALE; MALE; MOOD DISORDER; NAMED INVENTORIES, QUESTIONNAIRES AND RATING SCALES; OPEN STUDY; OUTCOME ASSESSMENT; PERVASIVE DEVELOPMENTAL DISORDER NOT OTHERWISE SPECIFIED; PRESCHOOL CHILD; PRIORITY JOURNAL; PSYCHOPHARMACOTHERAPY; RHINOPHARYNGITIS; RISK ASSESSMENT; SCHOOL CHILD; SOCIAL RESPONSIVENESS SCALE; STREPTOCOCCAL PHARYNGITIS; TREATMENT DURATION; UPPER ABDOMINAL PAIN; UPPER RESPIRATORY TRACT INFECTION; VOMITING;

ADOLESCENT; AKATHISIA, DRUG-INDUCED; BACLOFEN; CHILD; CHILD DEVELOPMENT DISORDERS, PERVASIVE; FEMALE; GABA-B RECEPTOR AGONISTS; HUMANS; IRRITABLE MOOD; MALE; TREATMENT OUTCOME;

EID: 84896405056     PISSN: 01623257     EISSN: 15733432     Source Type: Journal    
DOI: 10.1007/s10803-013-1963-z     Document Type: Article

References (31)

1. Aman, M. G.; McDougle, C. J.; Scahill, L.; Handen, B.; Arnold, L. E.; Johnson, C.; et al. (2009). Medication and parent training in children with pervasive developmental disorders and serious behavior problems: Results from a randomized clinical trial. Journal of the American Academy of Child and Adolescent Psychiatry, 48(12), 1143-1154.
2. Baudouin, S. J.; Gaudias, J.; Gerharz, S.; Hatstatt, L.; Zhou, K.; Punnakkal, P.; et al. (2012). Shared synaptic pathophysiology in syndromic and nonsyndromic rodent models of autism. Science, 338(6103), 128-132.
3. Bear, M. F.; Huber, K. M.; Warren, S. T. (2004). The mGluR theory of fragile X mental retardation. Trends Neuroscience, 27(7), 370-377. (Pubitemid 38829251)
4. Berry-Kravis, E. M.; Hessl, D.; Rathmell, B.; Zarevics, P.; Cherubini, M.; Walton-Bowen, K.; et al. (2012). Effects of STX209 (Arbaclofen) on neurobehavioral function in children and adults with fragile X syndrome: A randomized, controlled, phase 2 trial. Science translational medicine, 4(152), 152ra127.
5. Centers for Disease Control. (2012). Prevalence of autism spectrum disorders-autism and developmental disabilities monitoring network, 14 sites, United States, 2008. Morbidity and mortality weekly report. Surveillance summaries, 61(3), 1-19.
6. Fatemi, S. H.; Folsom, T. D.; Reutiman, T. J.; Thuras, P. D. (2009). Expression of GABA(B) receptors is altered in brains of subjects with autism. Cerebellum, 8(1), 64-69.
7. Gai, X.; Xie, H. M.; Perin, J. C.; Takahashi, N.; Murphy, K.; Wenocur, A. S.; et al. (2012). Rare structural variation of synapse and neurotransmission genes in autism. Molecular Psychiatry, 17(4), 402-411.
8. Gandal, M. J.; Edgar, J. C.; Ehrlichman, R. S.; Mehta, M.; Roberts, T. P.; Siegel, S. J. (2010). Validating gamma oscillations and delayed auditory responses as translational biomarkers of autism. Biological Psychiatry, 68(12), 1100-1106.
9. Geschwind, D. H. (2009). Advances in autism. Annual Review of Medicine, 60, 367-380.
10. Hagerman, R.; Hoem, G.; Hagerman, P. (2010). Fragile X and autism: Intertwined at the molecular level leading to targeted treatments. Mol Autism, 1(1), 12.
11. Henderson, C.; Wijetunge, L.; Kinoshita, M. N.; Shumway, M.; Hammond, R. S.; Postma, F. R.; et al. (2012). Reversal of disease-related pathologies in the fragile X mouse model by selective activation of GABAB receptors with arbaclofen. Science translational medicine, 4(152), 152ra128.
12. Huffman, L. C.; Sutcliffe, T. L.; Tanner, I. S.; Feldman, H. M. (2011). Management of symptoms in children with autism spectrum disorders: A comprehensive review of pharmacologic and complementary-alternative medicine treatments. Journal of Developmental and Behavioral Pediatrics, 32(1), 56-68.
13. Jahromi, L. B.; Kasari, C. L.; McCracken, J. T.; Lee, L. S.; Aman, M. G.; McDougle, C. J.; et al. (2009). Positive effects of methylphenidate on social communication and self-regulation in children with pervasive developmental disorders and hyperactivity. Journal of Autism and Developmental Disorders, 39(3), 395-404.
14. Kang, Y. H.; Sun, B.; Park, Y. S.; Park, C. S.; Jin, Y. H. (2012). GABA(A) and GABA(B) receptors have opposite effects on synaptic glutamate release on the nucleus tractus solitarii neurons. Neuroscience, 209, 39-46.
15. Kelleher, R. J.; 3rd, Geigenmuller, U.; Hovhannisyan, H.; Trautman, E.; Pinard, R.; Rathmell, B.; et al. (2012). High-throughput sequencing of mGluR signaling pathway genes reveals enrichment of rare variants in autism. PLoS One, 7(4), e35003.
16. Krueger, D. D.; Bear, M. F. (2011). Toward fulfilling the promise of molecular medicine in fragile X syndrome. Annual Review of Medicine, 62, 411-429.
17. Kumar, R. A.; Christian, S. L. (2009). Genetics of autism spectrum disorders. Current neurology and neuroscience reports, 9(3), 188-197.
18. McPheeters, M. L.; Warren, Z.; Sathe, N.; Bruzek, J. L.; Krishnaswami, S.; Jerome, R. N.; et al. (2011). A systematic review of medical treatments for children with autism spectrum disorders. Pediatrics, 127(5), e1312-e1321.
19. Michalon, A.; Sidorov, M.; Ballard, T. M.; Ozmen, L.; Spooren, W.; Wettstein, J. G.; et al. (2012). Chronic pharmacological mGlu5 inhibition corrects fragile X in adult mice. Neuron, 74(1), 49-56.
20. Oblak, A. L.; Gibbs, T. T.; Blatt, G. J. (2010). Decreased GABA(B) receptors in the cingulate cortex and fusiform gyrus in autism. Journal of Neurochemistry, 114(5), 1414-1423.
21. Paluszkiewicz, S. M.; Martin, B. S.; Huntsman, M. M. (2011). Fragile X syndrome: The GABAergic system and circuit dysfunction. Developmental Neuroscience, 33(5), 349-364.
22. Posey, D.; Erickson, C.; Stigler, K.; Diener, J.; Kieffer, E.; Kohn, A.; et al. (2009). A double-blind, placebo-controlled trial of N-acetylcysteine in children with autism spectrum disorders. Paper presented at the American College of Neuropsychopharmacology, 48th annual meeting, Hollywood, FL.
23. Posey, D. J.; Erickson, C. A.; McDougle, C. J. (2008). Developing drugs for core social and communication impairment in autism. Child and adolescent psychiatric clinics of North America, 17(4), 787-801, viii-ix.
24. Rubenstein, J. L.; Merzenich, M. M. (2003). Model of autism: Increased ratio of excitation/inhibition in key neural systems. Genes Brain Behavior, 2(5), 255-267. (Pubitemid 37345664)
25. Scahill, L.; Aman, M. G.; McDougle, C. J.; McCracken, J. T.; Tierney, E.; Dziura, J.; et al. (2006). A prospective open trial of guanfacine in children with pervasive developmental disorders. Journal of Child and Adolescent Psychopharmacology, 16(5), 589-598. (Pubitemid 44737213)
26. Scahill, L.; Hallett, V.; Aman, M. G.; McDougle, C. J.; Eugene Arnold, L.; McCracken, J. T.; et al. (2012). Brief report: Social disability in autism spectrum disorder: Results from research units on pediatric psychopharmacology (RUPP) autism network trials. Journal Autism Development Disorder, 43(3), 739-746.
27. Silverman, J. L.; Smith, D. G.; Rizzo, S. J.; Karras, M. N.; Turner, S. M.; Tolu, S. S.; et al. (2012). Negative allosteric modulation of the mGluR5 receptor reduces repetitive behaviors and rescues social deficits in mouse models of autism. Science translational medicine, 4(131), 131ra151.
28. Skafidas, E.; Testa, R.; Zantomio, D.; Chana, G.; Everall, I. P.; Pantelis, C. (2012). Predicting the diagnosis of autism spectrum disorder using gene pathway analysis. Molecular Psychiatry. doi: 10.1038/mp.2012.126.
29. State, M. W. (2010). The genetics of child psychiatric disorders: Focus on autism and Tourette syndrome. Neuron, 68(2), 254-269.
30. Watson, C.; Hoeft, F.; Garrett, A. S.; Hall, S. S.; Reiss, A. L. (2008). Aberrant brain activation during gaze processing in boys with fragile X syndrome. Archives of General Psychiatry, 65(11), 1315-1323.
31. Yizhar, O.; Fenno, L. E.; Prigge, M.; Schneider, F.; Davidson, T. J.; O'Shea, D. J.; et al. (2011). Neocortical excitation/inhibition balance in information processing and social dysfunction. Nature, 477(7363), 171-178.